What's New in Head and Neck Cancer: Key Findings in 2015-2016 From ECCO/ESMO, ASTRO, and the Multidisciplinary Head and Neck Cancer Symposium

Sue S. Yom, Apar Kishor P Ganti, Andreas Dietz

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Scientific investigation is extremely active in the treatment, management, and optimization of therapies for patients with head and neck cancer. These issues have undergone recent rapid evolution in response to a changing epidemiology based on an increasing proportion of HPV-associated oropharyngeal cancer with advances in multimodality technologies to improve outcomes and reduce toxicity. Choices of definitive treatment of various anatomic subsites are being refined, balancing the relative indications and advantages of surgery or chemoradiation-based strategies. The major potential influence of HPV-associated etiology on therapy selection, prognostic factors, response to treatment, survival outcomes, and post-treatment surveillance has created a robust and distinct field of scientific inquiry around this patient subset. Meanwhile, for patient subsets where prognosis remains poor, therapeutic intensification is being explored, and for recurrent/metastatic disease, improved selection for salvage and novel systemic therapies are under development. For all patients with head and neck cancer, upholding principles of equity and access to the highly specialized care that results in optimal outcomes should be the goal.

Original languageEnglish (US)
Pages (from-to)176-183
Number of pages8
JournalAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting
Volume35
DOIs
StatePublished - Jan 1 2016

Fingerprint

Head and Neck Neoplasms
Therapeutics
Oropharyngeal Neoplasms
Epidemiology
Technology
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{b3ca8cf39b2944be89d3ba33625cb9ef,
title = "What's New in Head and Neck Cancer: Key Findings in 2015-2016 From ECCO/ESMO, ASTRO, and the Multidisciplinary Head and Neck Cancer Symposium",
abstract = "Scientific investigation is extremely active in the treatment, management, and optimization of therapies for patients with head and neck cancer. These issues have undergone recent rapid evolution in response to a changing epidemiology based on an increasing proportion of HPV-associated oropharyngeal cancer with advances in multimodality technologies to improve outcomes and reduce toxicity. Choices of definitive treatment of various anatomic subsites are being refined, balancing the relative indications and advantages of surgery or chemoradiation-based strategies. The major potential influence of HPV-associated etiology on therapy selection, prognostic factors, response to treatment, survival outcomes, and post-treatment surveillance has created a robust and distinct field of scientific inquiry around this patient subset. Meanwhile, for patient subsets where prognosis remains poor, therapeutic intensification is being explored, and for recurrent/metastatic disease, improved selection for salvage and novel systemic therapies are under development. For all patients with head and neck cancer, upholding principles of equity and access to the highly specialized care that results in optimal outcomes should be the goal.",
author = "Yom, {Sue S.} and Ganti, {Apar Kishor P} and Andreas Dietz",
year = "2016",
month = "1",
day = "1",
doi = "10.14694/EDBK_161309",
language = "English (US)",
volume = "35",
pages = "176--183",
journal = "American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting",
issn = "1548-8756",
publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - What's New in Head and Neck Cancer

T2 - Key Findings in 2015-2016 From ECCO/ESMO, ASTRO, and the Multidisciplinary Head and Neck Cancer Symposium

AU - Yom, Sue S.

AU - Ganti, Apar Kishor P

AU - Dietz, Andreas

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Scientific investigation is extremely active in the treatment, management, and optimization of therapies for patients with head and neck cancer. These issues have undergone recent rapid evolution in response to a changing epidemiology based on an increasing proportion of HPV-associated oropharyngeal cancer with advances in multimodality technologies to improve outcomes and reduce toxicity. Choices of definitive treatment of various anatomic subsites are being refined, balancing the relative indications and advantages of surgery or chemoradiation-based strategies. The major potential influence of HPV-associated etiology on therapy selection, prognostic factors, response to treatment, survival outcomes, and post-treatment surveillance has created a robust and distinct field of scientific inquiry around this patient subset. Meanwhile, for patient subsets where prognosis remains poor, therapeutic intensification is being explored, and for recurrent/metastatic disease, improved selection for salvage and novel systemic therapies are under development. For all patients with head and neck cancer, upholding principles of equity and access to the highly specialized care that results in optimal outcomes should be the goal.

AB - Scientific investigation is extremely active in the treatment, management, and optimization of therapies for patients with head and neck cancer. These issues have undergone recent rapid evolution in response to a changing epidemiology based on an increasing proportion of HPV-associated oropharyngeal cancer with advances in multimodality technologies to improve outcomes and reduce toxicity. Choices of definitive treatment of various anatomic subsites are being refined, balancing the relative indications and advantages of surgery or chemoradiation-based strategies. The major potential influence of HPV-associated etiology on therapy selection, prognostic factors, response to treatment, survival outcomes, and post-treatment surveillance has created a robust and distinct field of scientific inquiry around this patient subset. Meanwhile, for patient subsets where prognosis remains poor, therapeutic intensification is being explored, and for recurrent/metastatic disease, improved selection for salvage and novel systemic therapies are under development. For all patients with head and neck cancer, upholding principles of equity and access to the highly specialized care that results in optimal outcomes should be the goal.

UR - http://www.scopus.com/inward/record.url?scp=85002285420&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002285420&partnerID=8YFLogxK

U2 - 10.14694/EDBK_161309

DO - 10.14694/EDBK_161309

M3 - Article

C2 - 27249698

AN - SCOPUS:85002285420

VL - 35

SP - 176

EP - 183

JO - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

JF - American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting

SN - 1548-8756

ER -